Cargando…

Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies

PURPOSE: The present study aimed to study the immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies. MATERIALS AND METHODS: This prospective cohort study of hematology patients aimed to evaluate their antibody levels against the receptor-binding domain of the severe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thookhamme, Chayapa, Navinpipat, Manassamon, Sasakul, Aimwipa, Pattarakosol, Pakthipa, Lertchaisataporn, Kamoltip, Tawinprai, Kriangkrai, Praditsuktavorn, Pannee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Vaccine Society 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193112/ https://www.ncbi.nlm.nih.gov/pubmed/37214149 http://dx.doi.org/10.7774/cevr.2023.12.2.107

Ejemplares similares

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
por: Porntharukchareon, Thachanun, et al.
Publicado: (2023)

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Rangsrisaeneepitak, Vimonsri, et al.
Publicado: (2022)

Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)
por: Muadchimkaew, Marisa, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population
por: Sirisreetreerux, Supamas, et al.
Publicado: (2023)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
por: Limpawittayakul, Piyarat, et al.
Publicado: (2022)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
por: Schmidt, Tina, et al.
Publicado: (2021)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
por: Chang, Jer-Hwa, et al.
Publicado: (2022)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
por: Öcal, Osman, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
por: Berlot, Giorgio, et al.
Publicado: (2022)

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19()
por: Morales Varas, G., et al.
Publicado: (2022)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
por: Garibashvili, Tamara, et al.
Publicado: (2022)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
por: Krutzke, Lea, et al.
Publicado: (2022)

Immunogenicity of Two Doses of ChAdOx1 nCoV-19 Vaccine in Lung Transplant Recipients
por: Carlier, F.M., et al.
Publicado: (2022)

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
por: Pinpathomrat, Nawamin, et al.
Publicado: (2022)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
por: Lin, Ting-Yun, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Lodge, Archie
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
por: Rogawski McQuade, Elizabeth T, et al.
Publicado: (2021)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination
por: Crane, Phillip, et al.
Publicado: (2021)

Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine
por: Lee, Hui Ping, et al.
Publicado: (2021)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
por: Ogbe, Ane, et al.
Publicado: (2022)

Post ChAdOx1 nCoV-19 vaccination frontal lobe syndrome
por: Tapdia, Madhusudan, et al.
Publicado: (2022)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
por: Casucci, Gerardo, et al.
Publicado: (2021)

Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
por: Atta, Syed Noman, et al.
Publicado: (2021)

Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine
por: Karimi Galougahi, Keyvan
Publicado: (2021)

Transient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine
por: Ahmer, Sadaf, et al.
Publicado: (2022)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
por: Kim, Jinnam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9v8mngo56msjk9taq88b8o8kul